Disorders of fatty acid metabolism: Pathology review

1,565views

Disorders of fatty acid metabolism: Pathology review

HMBP

HMBP

Glycolysis
Citric acid cycle
Electron transport chain and oxidative phosphorylation
Gluconeogenesis
Glycogen metabolism
Pentose phosphate pathway
Physiological changes during exercise
Amino acid metabolism
Nitrogen and urea cycle
Fatty acid synthesis
Fatty acid oxidation
Ketone body metabolism
Cholesterol metabolism
Essential fructosuria
Hereditary fructose intolerance
Galactosemia
Pyruvate dehydrogenase deficiency
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Lactose intolerance
Glycogen storage disease type I
Glycogen storage disease type II (NORD)
Glycogen storage disease type III
Glycogen storage disease type IV
Glycogen storage disease type V
Leukodystrophy
Metachromatic leukodystrophy (NORD)
Krabbe disease
Gaucher disease (NORD)
Niemann-Pick disease types A and B (NORD)
Niemann-Pick disease type C
Fabry disease (NORD)
Tay-Sachs disease (NORD)
Mucopolysaccharide storage disease type 1 (Hurler syndrome) (NORD)
Mucopolysaccharide storage disease type 2 (Hunter syndrome) (NORD)
Cystinosis
Hartnup disease
Alkaptonuria
Ornithine transcarbamylase deficiency
Phenylketonuria (NORD)
Cystinuria (NORD)
Homocystinuria
Maple syrup urine disease
Abetalipoproteinemia
Familial hypercholesterolemia
Hypertriglyceridemia
Hyperlipidemia
Disorders of carbohydrate metabolism: Pathology review
Disorders of fatty acid metabolism: Pathology review
Dyslipidemias: Pathology review
Glycogen storage disorders: Pathology review
Lysosomal storage disorders: Pathology review
Disorders of amino acid metabolism: Pathology review
Cellular structure and function
Cell membrane
Selective permeability of the cell membrane
Extracellular matrix
Cell-cell junctions
Endocytosis and exocytosis
Osmosis
Resting membrane potential
Nernst equation
Cytoskeleton and intracellular motility
Cell signaling pathways
Adrenoleukodystrophy (NORD)
Zellweger spectrum disorders (NORD)
Primary ciliary dyskinesia
Alport syndrome
Ehlers-Danlos syndrome
Osteogenesis imperfecta
Marfan syndrome
Vitamin C deficiency
Peroxisomal disorders: Pathology review
Nuclear structure
DNA structure
Transcription of DNA
Translation of mRNA
Gene regulation
Epigenetics
Amino acids and protein folding
Protein structure and synthesis
Nucleotide metabolism
DNA replication
Lac operon
DNA damage and repair
Cell cycle
Mitosis and meiosis
DNA mutations
Lesch-Nyhan syndrome
Orotic aciduria
Adenosine deaminase deficiency
Xeroderma pigmentosum
Li-Fraumeni syndrome
Bloom syndrome
Fanconi anemia
McCune-Albright syndrome
Acute radiation syndrome
Purine and pyrimidine synthesis and metabolism disorders: Pathology review
Polymerase chain reaction (PCR) and reverse-transcriptase PCR (RT-PCR)
Gel electrophoresis and genetic testing
ELISA (Enzyme-linked immunosorbent assay)
Karyotyping
DNA cloning
Fluorescence in situ hybridization
Mendelian genetics and punnett squares
Hardy-Weinberg equilibrium
Inheritance patterns
Independent assortment of genes and linkage
Evolution and natural selection
Down syndrome (Trisomy 21)
Edwards syndrome (Trisomy 18)
Patau syndrome (Trisomy 13)
Fragile X syndrome
Huntington disease
Myotonic dystrophy
Friedreich ataxia
Turner syndrome
Klinefelter syndrome
Prader-Willi syndrome
Angelman syndrome
Beckwith-Wiedemann syndrome
Cri du chat syndrome
Williams syndrome
Alagille syndrome (NORD)
Achondroplasia
Polycystic kidney disease
Familial adenomatous polyposis
Hereditary spherocytosis
Multiple endocrine neoplasia
Neurofibromatosis
Tuberous sclerosis
von Hippel-Lindau disease
Albinism
Cystic fibrosis
Hemochromatosis
Sickle cell disease (NORD)
Alpha-thalassemia
Beta-thalassemia
Wilson disease
X-linked agammaglobulinemia
Hemophilia
Muscular dystrophy
Wiskott-Aldrich syndrome
Mitochondrial myopathy
Autosomal trisomies: Pathology review
Muscular dystrophies and mitochondrial myopathies: Pathology review
Miscellaneous genetic disorders: Pathology review

Transcript

Watch video only

Two kids are brought to the clinic by their mothers. The first one’s Dalia, a 2 year old girl. Her mother is concerned because Dalia always seems to be tired and weak, and in general doesn’t eat much. On physical examination of the abdomen, you palpate an enlarged liver. You decide to run a blood test, which reveals that her blood glucose and ketone bodies are decreased, but what really stands out to you is that her carnitine levels are also really low.

After Dalia, you see Luca, a 3 year old boy who had a brief seizure earlier that day. Luca’s mother tells you that he’s had gastroenteritis for the past few days, so he’s been vomiting and not eating much. You decide to run a blood test, which also reveals low blood glucose and ketone bodies, but unlike Dalia, he has high levels of fatty acyl-carnitine.

Based on the initial presentation, both Dalia and Luca seem to have some fatty acid metabolism disorder. Now, let’s review fatty acid metabolism real quick. Normally, the body's main source of energy is the glucose we get from food. When glucose is running low, like with prolonged fasting or exercise, the body is able to obtain energy from stored fats.

The simplest form of fats are fatty acids, which are grouped by length into short, medium, long, and very long chain fatty acids. Short and medium chain fatty acids are primarily obtained from the diet, while long and very long chain fatty acids can be synthesized from acetyl-CoA by the liver and fat cells.

Now, keep in mind that acetyl-CoA is usually found in the mitochondrial matrix, whereas the enzymes required for fatty acid synthesis are all in the cytoplasm. For acetyl-CoA to cross the mitochondrial membranes and get to the cytoplasm, it first needs to combine with oxaloacetate to form citrate. Once in the cytoplasm, an enzyme called citrate lyase leaves citrate back into acetyl-CoA and oxaloacetate. This whole process is called the citrate shuttle.

Now, when the body needs some extra energy, fatty acids can be broken down by the acyl-CoA dehydrogenases into smaller chain fatty acids to ultimately obtain acetyl-CoA. This process is called fatty acid or beta oxidation. To do this, fatty acids need to leave the fat cells, and enter the bloodstream, where they bind to a protein called albumin.

Albumin carries the fatty acids to the heart, skeletal muscle, and liver cells, which is where fatty acid oxidation mainly takes place. Once inside these cells, a cytosolic enzyme called fatty acyl-CoA synthetase adds a coenzyme A or CoA molecule to the end of the fatty acid, turning it into a fatty acyl-CoA.

Now, oxidation of very long chain fatty acyl-CoAs takes place in the peroxisomes, and that’s another topic; on the other hand, oxidation of short, medium, and long chain fatty acyl-CoAs takes place in the mitochondrial matrix. What’s important here is that short and medium chain fatty acyl-coAs can freely cross the mitochondrial membranes, while the long chain fatty acyl-CoAs can’t.

To get around this problem, an enzyme within the outer mitochondrial membrane called carnitine palmitoyltransferase 1 or CPT1 replaces the CoA with a carnitine, making fatty acyl-carnitine and a free CoA, both of which can easily cross the inner mitochondrial membrane. Then, along the inner mitochondrial membrane, another enzyme called carnitine palmitoyltransferase 2 or CPT2 substitutes carnitine and CoA back, therefore regenerating fatty acyl-CoA and free carnitine within the mitochondrial matrix. This whole process is called the carnitine shuttle, and it’s very high yield.

With prolonged starvation, fatty acid oxidation ramps up, and the excess acetyl-CoA is sent to the liver to get converted into ketone bodies. These ketone bodies are then released into the bloodstream, so that they can reach the rest of the body and be used to obtain energy.

Now, fatty acid metabolism disorders result from a defect of an enzyme involved in obtaining energy sources like acetyl-CoA and ketone bodies from fatty acids. For your exams, the two most high yield fatty acid metabolism disorders are systemic carnitine deficiency and medium chain acyl-CoA dehydrogenase deficiency.

Let’s begin with systemic carnitine deficiency, in which there’s not enough carnitine available to assist in the carnitine shuttle. Systemic carnitine deficiency can be primary or secondary. Systemic primary carnitine deficiency, or SPCD for short, is caused by a mutation in the SLC22A5 gene, which codes for the organic cation transporter protein OCTN2.

For your exams, remember that this is an autosomal recessive disease, meaning that an individual needs to inherit two copies of the mutated gene, one from each parent, to develop the condition. Now, OCTN2 is a carnitine transporter that would normally help reabsorb carnitine in kidneys, as well as transport carnitine inside cells capable of fatty acid oxidation.

As a result, in primary carnitine deficiency, most of the carnitine ends up being excreted in urine, leading to a carnitine shortage in the body. And even that little carnitine available can’t be transported inside the cells to be used in the carnitine shuttle. As a result, long chain fatty acids can’t get into the mitochondria, so fatty acid oxidation is impaired.

Systemic primary carnitine deficiency often first manifests in infants or young children as fatigue and weakness. In addition, the child may show irritability and feeding difficulties. What’s most important for your exams is that, during fasting, individuals may experience hypoketotic hypoglycemia, which is basically an episode of low blood sugar that can’t be compensated by producing ketone bodies to obtain energy.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Fetal Fatty Acid Oxidation Disorders, Their Effect on Maternal Health and Neonatal Outcome: Impact of Expanded Newborn Screening on Their Diagnosis and Management" Pediatric Research (2005)
  6. "A Fetal Fatty-Acid Oxidation Disorder as a Cause of Liver Disease in Pregnant Women" New England Journal of Medicine (1999)